Recombinant Mouse Angiopoietin-like Protein 4/ANGPTL4, CF

When Recombinant Mouse Angiopoietin‑likeProtein 4/ANGPTL4 (Catalog# 9797-AN) is immobilized at 1 μg/mL,100 μL/well, Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4) binds with an ED50 of 0.09‑0.54 μg/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Angiopoietin-like Protein 4/ANGPTL4, CF Summary

• Additional Information: C-Terminal Fragment
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse Angiopoietin‑like Protein 4/ANGPTL4 is immobilized at 1 μg/mL, 100 μL/well, the concentration of LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4) that produces 50% of the optimal binding response is 0.09-0.54 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse Angiopoietin-like Protein 4/ANGPTL4 protein
  Leu169-Ser410, with a C-terminal 6-His tag
• Accession #: Q9Z1P8
• N-terminal Sequence: Leu169
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 28 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 36-43 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Angiopoietin-like Protein 4/ANGPTL4, CF

• Angiopoietin like Protein 4
• angiopoietin-like 4
• Angiopoietin-like Protein 4
• ANGPTL4
• ARP4fasting-induced adipose factor
• FIAF
• FIAFhepatic angiopoietin-related protein
• Hepatic fibrinogen/angiopoietin-related protein
• HFARP
• HFARPANGPTL2
• NL2
• peroxisome proliferator-activated receptor (PPAR) gamma inducedangiopoietin-related protein
• PGAR
• PGARangiopoietin-related protein 4
• pp1158
• PPARG angiopoietin related protein

Background

Angiopoietin-like 4 (ANGPTL4), also known as FIAF, FARP, and PGAR, is a 55 kDa glycoprotein secreted by the liver and fat tissue. It is structurally related to the angoipoietins and contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain which can be proteolytically separated in vivo (1). Amino acid 169‑410 contains the C-terminal fibrinogen like domain within mouse ANGPTL4, and this domain shares 75% and 97% sequence identity with human and rat homologs, respectively. The coiled coil domain, which is not glycosylated, mediates the formation of variable sized disulfide-linked oligomers (2). This domain directly inhibits lipoprotein lipase, resulting in increased circulating triglyceride levels (3, 4). In humans, the N-terminal fragment and full length ANGPTL4 physically associate with HDL (4). In mouse, however, full length ANGPTL4 associates with HDL, while the N-terminal fragment associates with LDL (4). Circulating ANGPTL4 is decreased in type II diabetics with a subsequent loss of its normal plasma glucose lowering activity (5). Its expression in adipose tissue is induced by fasting and suppressed by feeding (6). In hypoxic areas, ANGPTL4 is induced in both vascular endothelial cells and tumor cells (7, 8). The N-terminal fragment can function as an angiogenesis inhibitor (7, 8). In contrast, the C-terminal fragment modulates cell adhesion through interactions with heparan sulfate proteoglycans, Integrins beta 1 and beta 5, Vitronectin, and Fibronectin, thereby promoting keratinocyte migration and wound healing (7, 9, 10). ANGPTL4 additionally enhances the survival of hematopoietic and mesenchymal stem cells (11, 12). The expression of an undersialylated form of ANGPTL4 in renal podocytes contributes to proteinuria and nephrotic syndrome (13). The immune-inhibitory receptor human leukocyte immunoglobulin-like receptor B2 (LILRB2) and its mouse orthologue paired immunoglobulin-like receptor (PIRB) have been identified as receptors for several ANGPTLs (14) including ANGPTL4.

1. Zhu, P. et al. (2012) Biosci. Rep. 32:211.
2. Ge, H. et al. (2004) J. Biol. Chem. 279:2038.
3. Sukonina, V. et al. (2006) Proc. Natl. Acad. Sci. USA 103:17450.
4. Mandard, S. et al. (2006) J. Biol. Chem. 281:934.
5. Xu, A. et al. (2005) Proc. Natl. Acad. Sci. USA 102:6086.
6. Kersten, S. et al. (2000) J. Biol. Chem. 275:28488.
7. Cazes, A. et al. (2006) Circ. Res. 99:1207.
8. Le Jan, S. et al. (2003) Am. J. Pathol. 162:1521.
9. Goh, Y.Y. et al. (2010) Am. J. Pathol. 177:2791.
10. Goh, Y.Y. et al. (2010) J. Biol. Chem. 285:32999.
11. Blank, U. et al. (2012) Eur. J. Haematol. 89:198.
12. Hou, M. et al. (2014) PLoS ONE 9:e85808.
13. Clement, L.C. et al. (2011) Nat. Med. 17:117.
14. Zhang, C.C. et al. (2012) Nature 485:656.

Bioinformatics

• Uniprot:
  • Q9Z1P8()